Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.
Cell Prolif. 2021 Oct;54(10):e13115. doi: 10.1111/cpr.13115. Epub 2021 Aug 31.
The chemokine ligand CCL2 and its receptor CCR2 are implicated in the initiation and progression of various cancers. CCL2 can activate tumour cell growth and proliferation through a variety of mechanisms. By interacting with CCR2, CCL2 promotes cancer cell migration and recruits immunosuppressive cells to the tumour microenvironment, favouring cancer development. Over the last several decades, a series of studies have been conducted to explore the CCL2-CCR2 signalling axis function in malignancies. Therapeutic strategies targeting the CCL2- CCR2 axis have also shown promising effects, enriching our approaches for fighting against cancer. In this review, we summarize the role of the CCL2-CCR2 signalling axis in tumorigenesis and highlight recent studies on CCL2-CCR2 targeted therapy, focusing on preclinical studies and clinical trials.
趋化因子配体 CCL2 及其受体 CCR2 参与多种癌症的发生和发展。CCL2 可以通过多种机制激活肿瘤细胞的生长和增殖。通过与 CCR2 相互作用,CCL2 促进癌细胞迁移并招募免疫抑制细胞到肿瘤微环境中,有利于癌症的发展。在过去的几十年中,已经进行了一系列研究来探索 CCL2-CCR2 信号轴在恶性肿瘤中的功能。针对 CCL2-CCR2 轴的治疗策略也显示出了有希望的效果,丰富了我们对抗癌症的方法。在这篇综述中,我们总结了 CCL2-CCR2 信号轴在肿瘤发生中的作用,并强调了最近关于 CCL2-CCR2 靶向治疗的研究,重点是临床前研究和临床试验。